ATP结合盒转运体与肝癌化疗耐药相关性的研究进展  

Research progress on correlation between ATP binding cassette transports and multidrug resistance of liver cancer

作　　者：刘文斌[1] 曹广文[1] 

机构地区：[1]第二军医大学流行病学教研室,上海200433

出　　处：《上海预防医学》2017年第4期249-252,287,共5页Shanghai Journal of Preventive Medicine

基　　金：国际合作与交流项目(81520108021);国家重点基础研究发展计划(2015CB554000)

摘　　要：化疗多药耐药是当前肝癌治疗的主要问题。ATP结合盒(ABC)转运体家族通过诱导肿瘤细胞药物外排导致耐药。ABCB1是介导肝癌耐药的主要ABC转运体亚型,其表达与肝癌细胞的干性特征相关。炎症和癌症相关的多种信号通路关键分子协同调节了ABC转运体的表达。维拉帕米可以通过抑制ABCB1功能而逆转肝癌的耐药性。对于ABC转运体和肝癌耐药性的深入研究可以进一步完善癌症治疗策略,降低患者死亡率。Multidrug resistance （ MDR ） is a major problem in the current treatment of liver cancer. ATP binding cassette （ABC） transports induce drug effluxes in cancer cells, thus contributing to MDR. ABCB1 is a main subtype of ABC transports that mediates the MDR of liver cancer. The expression of ABCB1 is related to the stemness characteristics of liver cancer cells. The key molecules of a variety types of signaling pathways related to inflammation and cancer collaborate with one another and adjust the expression of ABC transports. Verapamil can reverse the MDR of liver cancer through inhibiting ABCB1. Further investigations of the relation between ABC transporters and the MDR in liver cancer can improve treatment strategy for cancer and reduce mortality.

关 键 词：肝癌 多药耐药 ATP结合盒转运体 维拉帕米 

分 类 号：R735.7[医药卫生—肿瘤]